Antisense therapy in oncology: New hope for an old idea?

Lancet

Volumn 358, Issue 9280, 2001, Pages 489-497

  Tamm, Ingo ^a   Dörken, Bernd ^a   Hartmann, Gunther ^b  

^a HUMBOLDT UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CGP 69846A; CYCLIC AMP DEPENDENT PROTEIN KINASE; DNA METHYLTRANSFERASE; FOMIVIRSEN; GENE EXPRESSION MODULATOR 231; ISIS 2503; ISIS 3521; MESSENGER RNA; MG 98; OBLIMERSEN; PROTEIN BCL 2; PROTEIN KINASE C; PROTEIN MDM2; RAF PROTEIN; RAS PROTEIN; SURVIVIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; B CELL LYMPHOMA; CANCER CELL CULTURE; CARCINOMA; CLINICAL TRIAL; DNA HYBRIDIZATION; DRUG APPROVAL; DRUG DESIGN; DRUG EFFECT; DRUG TOLERABILITY; GENE THERAPY; HUMAN; MELANOMA; NONHUMAN; ONCOGENE C MYB; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN MOTIF; PROTEIN TARGETING; RETINITIS; REVIEW; RNA TRANSLATION;

EID: 0035845318     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(01)05629-X     Document Type: Review

References (99)

1. Antisense therapeutics in chronic myeloid leukaemia: The promise, the progress and the problems
2. Nucleic acid therapeutics: State of the art and future prospects
3. Elucidating cell signaling mechanisms using antisense technology
4. Molecular mechanisms of action of antisense drugs
5. Novel mechanisms for antisense-mediated regulation of gene expression
6. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-hodgkin's lymphoma
7. Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer
8. A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continous intravenous infusion in patients with advanced cancer
9. Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A)
10. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer
11. Antisense approaches enter the clinic
12. Structural gene identification and mapping by DNA-mRNA hybrid-arrested cell-free translation
13. Inhibition of Rous sarcoma virus replication and transformation by a specific oligodeoxynucleotide
14. Inhibition of rous sarcoma viral RNA translation by a specific oligodeoxynucleotide
15. History of antisense oligonucleotides
16. Translational control of IS10 transposition
17. Oligonucleotide therapeutics: A step forward
18. In vivo modulation of N-myc expression by continous perfusion with an antisense oligonucleotide
19. Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice
20. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function
21. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy
22. MDM2 oncogene as a target for cancer therapy: An antisense approach
23. Induction of apoptosis in lung cancer cells following bcl-xL antisense treatment
24. The NF-kappaB transcription factor in oncogenesis
25. Antisense oligonucleotides demonstrate a dominant role of c-Ki-RAS proteins in regulating the proliferation of diploid human fibroblasts
26. Selective inhibition of A-Raf and C-Raf mRNA expression by antisense oligodeoxynucleotides in rat vascular smooth muscle cells: Role of A-Raf and C-Raf in serum-induced proliferation
27. Inhibition of chronic myelogenous leukaemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction
28. Evaluation of biological role of c-Jun N-terminal kinase using an antisense approach
29. Treatment of prostate cancer in vitro and in vivo with 2-5A-anti-telomerase RNA component
30. Human promyelocytic leukaemia HL60 cell proliferation and c-MYC protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-MYC mRNA
31. An oligomer complementary to c-MYC mRNa inhibits proliferation of HL60 promyelocytic cells and induces differentiation
32. An oligomer complementary to c-myb-encoded mRNA inhibits proliferation of human myeloid leukemia cell lines
33. Antisense-medited inhibition of protein synthesis
34. Novel anticancer drug discovery
35. Antisense therapy of hematologic malignancies
36. A review of issues in the pharmacokinetics and toxicology of phophorothioate antisense oligonucleotides
37. Fomivirsen: A phosphorothioate oligonucleotide for the treatment of CMV retinitis
38. Antisense tumor therapy
39. The bcl-2 protein family: Arbiters of cell survival
40. Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance
41. Bcl-2 expression in cutaneous malignant melanoma and benign melanocytic nevi
42. Chemosensitization of malignant melanoma by BCL2 antisense therapy
43. A phase I study of bcl-2 antisense G3139 (GENTA) and weekly docetaxel in patients with advanced breast cancer and other solid tumors
44. A phase I, pharmacokinetic and biologic correlative study of G3139 (Bcl-2 antisense oligonucleotide) and Docetaxel in patients with hormone-refractory prostate cancer (HRPC)
45. A phase I trial of an antisense oligonucleotide to bcl-2 (G3139, Genta) and mitoxantrone in patients with metastatic hormone refractory prostate cancer (HRPC)
46. A phase I/II trial of ISIS 3521, an antisense inhibitor of protein kinase C alpha, combined with carboplatin and paclitaxel in patients with non-small cell lung cancer
47. Phase I/II trial of ISIS 3521, an antisense inhibitor of PKC, with carboplatin and paclitaxel in non-small cell lung cancer
48. Efficacy, toxicity, and pharmacology of an antisense oligonucleotide directed against protein kinase C-alpha (ISIS 3521) delivered as a 21 day continous intravenous infusion in patients with recurrent high grade astrocytomas (HGA)
49. Ras oncogenes in human cancer: A review
50. Regulators and effectors of ras protein
51. Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors
52. c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A)
53. Phase II study of c-raf kinase antisense oligonucleotide ISIS 5132 in patients with recurrent ovarian cancer
54. A phase II trial of ISIS 2503, an antisense inhibitor of H-ras, as first line therapy for advanced colorectal carcinoma
55. Oligonucleotide therapeutics for hematologic disorders
56. A phase I and pharmacokinetik (PK) study of the human DNA methyltransferase (Metase) antisense oligodeoxynucleotide MG98 given as a 21-day continous infusion every 4 weeks
57. Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIalpha subunit of protein kinase A after oral administration
58. Mechanism and function of a newly identified CpG DNA motif in human primary B cells
59. Oligodeoxynucleotides enhance lipopolysaccharide-stimulated synthesis of tumor necrosis factor: Dependence on phophorothioate modifications and reversal by heparin
60. CpG DNA as a signal for growth, activation and maturation of human dendritic cells
61. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo
62. Mechanism of action of CpG DNA
63. A toll-like receptor recognizes bacterial DNA
64. Causing a commotion in the blood: Immunotherapy progresses from bacteria to bacterial DNA
65. Bias in nucleotide composition of antisense oligonucleotides
66. CpG DNA in cancer immunotherapy
67. Eradication of human non Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low dose cyclophosphamide
68. CpG DNA increases immunogenicity and target-antigen expression of primary B cell non-Hodgkin lymphoma cells
69. IAP family proteins: Suppressors of apoptosis
70. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias
71. X-linked IAP is a direct inhibitor of cell death proteases
72. A single BIR domain of XIAP sufficient for inhibiting caspases
73. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas
74. Fusion between the apoptosis inhibitor gene API2 and a novel 18q gene MLT, rearranged in the t(11;18)(q21;q21), marks half of the gastro-intestinal MALT-type lymphomas without large cell proliferation
75. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma
76. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs
77. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas
78. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer
79. A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers
80. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma
81. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma
82. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas
83. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer
84. Livin, a novel inhibitor-of-apoptosis (IAP) family member
85. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma
86. Control of apoptosis and mitotic spindle checkpoint by survivin
87. Survivin initiates cell cycle entry by the competitive interaction with Cdk-4/p16INK4a and Cdk2/Cyclin E complex activation
88. Survivin' cell-separation anxiety
89. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy
90. Down-regulation of survivin by antisense oligonucleotides in plasmocytoma cells leads to increased apoptosis and sensitivity to chemotherapeutic drugs
91. Escaping cell death: Survival proteins in cancer
92. Thermal response of rat fibroblasts stably transfected with the human 70-kDa heat shock protein-encoding gene
93. Heat shock resistance conferred by expression of the human HSP27 gene in rodent cells
94. Expression of the heat shock protein HSP27 in human ovarian cancer
95. Overexpression of resistance-related proteins (metallothioneins, glutathione-S-transferase pi, heat shock protein 27, and lung resistance-related protein) in osteosarcoma: Relationship with poor prognosis
96. The role of chromosome translocations in leukemogenesis
97. A revised european-american classification of lymphoid neoplasms: A proposal from the international study group
98. Telomerase as a potential molecular target to study G-quartet phosphorothioates
99. Morpholino antisense oligomers: The case for an RNase H-independent structural type